Skip to main
MGX
MGX logo

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc., a genetic medicines company, has developed a proprietary genome editing toolbox that shows significant promise in addressing various disorders, including Hemophilia A, with notable results showcased through durable FVIII levels of 80% after 19 months in clinical trials. The company's strategy includes a robust pipeline focused on in vivo gene editing while also exploring technology out licensing for ex vivo cell therapies, indicating diverse revenue-generating opportunities. With a strong commitment to developing curative therapeutics and a clear focus on innovative solutions within the genetic medicine field, Metagenomi is well-positioned for future growth and financial success.

Bears say

Metagenomi Inc. reported a net loss of $19.9 million in 2Q25, translating to a loss of $0.54 per share, reflecting ongoing financial challenges. The company faces significant risks, including potential delays in advancing its pipeline candidates through clinical assessments, which could hinder progress particularly in critical areas like Hemophilia A and TTR. Additionally, concerns regarding the possibility of long-term dilution risk further contribute to a negative outlook for the company's financial performance.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.